Helen Mann, MSc

Senior Director, Statistics
AstraZeneca
Cambridge, United Kingdom

Presentation(s):

• 90: Pathological complete response to FLOT chemotherapy with or without durvalumab in resectable gastric and gastroesophageal junction cancer: subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study

  Friday, March 22, 2024
  10:42am – 10:52am ET